Audra Lynn Stinchcomb

This inventor holds 20 USPTO granted patents and 22 published patent applications, plus 11 CIPO patents and 13 EPO patents, primarily in Transdermal Drug Delivery. Top assignees: Alltranz Inc., University of Kentucky Research Foundation, Zynerba Pharmaceuticals, Inc.. Active years: 2003-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Audra Lynn Stinchcomb. Retrieved from https://idiyas.com/inventor/audra-lynn-stinchcomb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 22)

% Patents Active = 65.0

CIPO Patents = 11 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 3.4

ph-index = 12

Forward Citations = 420(Granted Patents)

Location History:

Latham, NY (US) (2003 - 2007)
Lexington, KY (US) (2007 - 2017)
Baltimore, MD (US) (2017)
Ruxton, MD (US) (2017 - 2019)

Company Filing History:

University of Kentucky Research Foundation

patents

4 out of 13

Zynerba Pharmaceuticals, Inc.

patents

4. 2 out of 3

Buzzz Pharmaceuticals Limited

patents

5. 1 out of 2,029

University System of Maryland

7. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2019

Loading Chart...

Areas of Expertise:

Transdermal Patch

Microneedle

Opioid Antagonist

Cannabidiol Prodrugs

Tetrahydrocannabinol

Abuse Deterrent

Drug Delivery System

Cox Inhibitor

Oral Bioavailable

Sustained Release

Topical Administration

Nanodevices

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10238648 - Abuse deterrent opioid/opioid-antagonist transdermal patch (2019-03-26),

2. 10071090 - Oxymorphone transdermal patch (2018-09-11),

3. 10022366 - Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery (2018-07-17),

4. 9957246 - Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same (2018-05-01),

5. 9695143 - Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same (2017-07-04),

6. 9566341 - Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same (2017-02-14),

7. 9533942 - Use of cannabidiol prodrugs in topical and transdermal administration with microneedles (2017-01-03),

8. 8980942 - Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same (2015-03-17),

9. 8653271 - Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion (2014-02-18),

10. 8481560 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists (2013-07-09),

11. 8449908 - Transdermal delivery of cannabidiol (2013-05-28),

12. 8435556 - Transdermal delivery of cannabidiol (2013-05-07),

13. 8309568 - Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs (2012-11-13),

14. 8293786 - Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same (2012-10-23),

15. 8227627 - Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same (2012-07-24),

Title: Audra Lynn Stinchcomb: Innovator in Transdermal Drug Delivery Systems

Introduction

Audra Lynn Stinchcomb is a distinguished inventor located in Lexington, KY, known for her significant contributions to the field of transdermal drug delivery. With a remarkable total of 20 patents, her innovative work seeks to enhance treatment options for patients, particularly focusing on pain management and abuse deterrence.

Latest Patents

Among her latest patents, Stinchcomb developed an "Abuse deterrent opioid/opioid-antagonist transdermal patch," which features a multilaminate design. This multilaminate includes a first layer containing an opioid analgesic compound and a pressure-sensitive adhesive, complemented by a second layer of an opioid antagonist. Additionally, a barrier layer is strategically placed between the opioid and antagonist layers to enhance protection against misuse.

Another significant patent attributed to her is the "Oxymorphone transdermal patch," which also falls under the realm of pain management. This innovation describes a transdermal patch that utilizes oxymorphone to provide effective pain relief, along with detailed processes for preparing these patches effectively.

Career Highlights

Stinchcomb has showcased her expertise while working with notable organizations, including Alltranz Inc. and the University of Kentucky Research Foundation. Her focus on transdermal systems has cemented her status as a key player in pharmaceutical innovations.

Collaborations

During her career, Stinchcomb has collaborated with esteemed professionals, including Miroslaw Jerzy Golinski and Dana Carmel Hammell. These partnerships have proven to be instrumental in the development and refinement of her inventions, further pushing the boundaries of drug delivery technologies.

Conclusion

Audra Lynn Stinchcomb stands out as an innovative force in the realm of transdermal drug delivery systems. Her extensive patent portfolio, particularly the recent advancements in abuse deterrent technologies, reflects her commitment to improving patient outcomes in medical treatment. As she continues her work, her contributions to the field will undoubtedly make a lasting impact.

Profile summary based on public USPTO records.